Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07203352CT.gov Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL | — | Recruiting | — | — | — |
NCT05751044CT.gov HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Recruiting | — | — | — |
NCT06855810CT.gov Newly-diagnosed Pediatric T-cell ALL Protocol | — | Recruiting | — | — | — |
NCT06533748CT.gov Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | — | Recruiting | — | — | — |
NCT04845035CT.gov Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Withdrawn | — | — | — |
NCT05993949CT.gov Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT05192889CT.gov Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | — | Active Not Recruiting | — | — | — |
NCT04747912CT.gov Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | — | Recruiting | — | — | — |
NCT04603872CT.gov CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
Show 26 more trialsShow fewer
NCT04329325CT.gov Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03318770CT.gov Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT03414450CT.gov Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | — | Withdrawn | — | — | — |
NCT03515200CT.gov Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT02744768CT.gov D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT03117751CT.gov Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03023046CT.gov Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT02815059CT.gov Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone | — | Withdrawn | — | — | — |
NCT03564470CT.gov Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | — | Unknown | — | — | — |
NCT02779283CT.gov Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02523976CT.gov Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02143414CT.gov Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02494882CT.gov Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | — | Active Not Recruiting | — | — | — |
NCT02043587CT.gov Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT01620216CT.gov Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | — | Terminated | — | — | — |
NCT01256398CT.gov Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01004497CT.gov First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | — | Completed | — | — | — |
NCT00792948CT.gov Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT00940524CT.gov Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00720109CT.gov Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00549848CT.gov Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02888990CT.gov Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00349518CT.gov Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | — | Withdrawn | — | — | — |
NCT00390793CT.gov Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
NCT00391989CT.gov Treatment of Adult Ph+ LAL With BMS-354825 | — | Completed | — | — | — |
NCT00298987CT.gov A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dasatinib (this asset) | Nanfang Hospital, Southern Medical University | P3 | B · 62 |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Daunomycin | PETHEMA Foundation | P4 | BB |
| Methotrexate | Princess Maxima Center for Pediatric Oncology | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P4 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for Dasatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 68 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- DaunomycinPETHEMA FoundationBB
Citation
Floatz Terminal. Dasatinib in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dasatinib-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →